| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S100 |
| Uniprot No | P04271 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-92aa |
| 氨基酸序列 | MSELEKAMVALIDVFHQYSGREGDKHKLKKSELKELINNELSHFLEEIKE QEVVDKVMETLDNDGDGECDFQEFMAFVAMVTTACHEFFEHE |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与S100重组蛋白相关的文献示例(注：文献信息为示例性质，具体内容需核实原文)：
---
1. **文献名称**: *"Recombinant human S100A8/A9 protein induces pro-inflammatory cytokines in macrophages via TLR4 signaling"*
**作者**: Wang Y, et al.
**摘要**: 研究利用大肠杆菌表达系统成功制备重组人S100A8/A9异源二聚体，证实其通过TLR4受体激活巨噬细胞释放IL-6和TNF-α，揭示其在炎症性疾病中的潜在机制。
2. **文献名称**: *"Structural and functional analysis of recombinant S100B protein in a glioblastoma model"*
**作者**: Leclerc E, et al.
**摘要**: 通过重组表达S100B蛋白，结合核磁共振技术解析其钙离子结合后的构象变化，并证明其在胶质母细胞瘤中通过激活RAGE通路促进肿瘤细胞侵袭。
3. **文献名称**: *"High-yield production of recombinant S100A4 for antibody generation and cancer metastasis studies"*
**作者**: Schneider M, et al.
**摘要**: 优化了重组S100A4蛋白的真核表达体系，获得高纯度蛋白用于制备单克隆抗体，实验表明其通过调节细胞骨架动力学增强癌细胞转移能力。
---
**提示**：以上文献信息为基于领域研究的概括性示例，实际引用时建议通过PubMed或Web of Science检索关键词“recombinant S100 protein”获取真实文献。
The S100 protein family comprises a group of calcium-binding proteins involved in diverse cellular processes, including inflammation, differentiation, and cancer progression. First identified in the 1960s, S100 proteins are characterized by two EF-hand calcium-binding domains and low molecular weights (10-12 kDa). The name "S100" originates from their solubility in 100% ammonium sulfate. Over 20 human S100 proteins have been identified (e.g., S100A8. S100A9. S100B), each exhibiting cell-specific expression patterns and functional diversity. These proteins act as intracellular calcium sensors and extracellular signaling molecules through receptor-mediated pathways such as RAGE (Receptor for Advanced Glycation Endproducts).
Recombinant S100 proteins are engineered using expression systems (typically E. coli or mammalian cells) to study their structure-function relationships and pathological roles. Their production enables research into calcium-dependent conformational changes, protein-protein interactions, and disease mechanisms. S100 proteins are implicated in numerous pathologies: S100A8/A9 heterodimers drive inflammation in autoimmune diseases, S100B serves as a biomarker for brain injury and melanoma, while various S100 members promote tumor growth and metastasis via microenvironment modulation.
Therapeutic strategies targeting S100 proteins include small-molecule inhibitors, monoclonal antibodies, and gene silencing approaches. Recombinant forms are also used in diagnostic assays and vaccine development. Challenges remain in understanding isoform-specific functions and minimizing off-target effects during therapeutic intervention. Current research focuses on deciphering their roles in cellular communication, disease-specific post-translational modifications, and potential as precision medicine targets.
×
